浸润性膀胱癌预后的生物学标志物 - Suppr

Suppr

超能文献

Biological markers of prognosis in invasive bladder cancer.

作者信息

Fradet Y

机构信息

Department of Surgery/Urology, Laval University Cancer Research Center, Québec, Canada.

出版信息

Semin Oncol. 1990 Oct;17(5):533-43.

PMID:2218565

Abstract

摘要

相似文献

Biological markers of prognosis in invasive bladder cancer.浸润性膀胱癌预后的生物学标志物

Semin Oncol. 1990 Oct;17(5):533-43.

[Prognostic markers in transitional carcinoma of the bladder].[膀胱移行癌的预后标志物]

Arch Esp Urol. 1991 Jan-Feb;44(1):47-52.

Bladder cancer biomarkers: current developments and future implementation.膀胱癌生物标志物：当前进展与未来应用

Curr Opin Urol. 2007 Sep;17(5):341-6. doi: 10.1097/MOU.0b013e3282c8c72b.

Molecular pathology of non-invasive urothelial carcinomas (part I).非浸润性尿路上皮癌的分子病理学（第一部分）

Virchows Arch. 2003 Apr;442(4):309-16. doi: 10.1007/s00428-002-0748-0. Epub 2003 Feb 11.

DNA flow cytometry and 67Ki proliferating index as prognostic factors of early recurrence and progression in G1-G2/Ta-T1 and G3/Ta-T1 transitional cell carcinoma of the bladder.DNA流式细胞术和67Ki增殖指数作为G1-G2/Ta-T1期和G3/Ta-T1期膀胱移行细胞癌早期复发和进展的预后因素

Minerva Urol Nefrol. 1997 Sep;49(3):141-3.

Neoadjuvant chemotherapy for invasive bladder cancer: future directions.浸润性膀胱癌的新辅助化疗：未来方向

Semin Oncol. 1990 Oct;17(5):635-8.

Biomarkers for the detection of bladder cancer.用于检测膀胱癌的生物标志物。

Adv Anat Pathol. 2001 Jan;8(1):37-45. doi: 10.1097/00125480-200101000-00006.

Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.Foxo3和Foxo4表达与膀胱癌临床病理特征及预后的相关性

Pathol Res Pract. 2017 Jul;213(7):766-772. doi: 10.1016/j.prp.2017.04.004. Epub 2017 Apr 20.

Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.碳酸酐酶IX在膀胱癌中的作用：一种诊断、预后及治疗的分子标志物

Cancer. 2009 Apr 1;115(7):1448-58. doi: 10.1002/cncr.24163.

EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder.上皮细胞黏附分子（EpCAM）主要表达于高级别和晚期膀胱尿路上皮癌。

J Clin Pathol. 2008 Mar;61(3):307-10. doi: 10.1136/jcp.2007.049460. Epub 2007 Jun 22.

引用本文的文献

Contemporary Management of Bladder Cancer: Identifying patients who are at risk.膀胱癌的当代管理：识别有风险的患者。

Can Fam Physician. 1991 Jun;37:1469-77.

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer.评估表皮生长因子受体、转化生长因子α、表皮生长因子和c-erbB2在浸润性膀胱癌进展中的作用。

Urol Res. 1997;25(1):9-17. doi: 10.1007/BF00941900.

Short-term culture of exfoliated cells from the urine of patients with bladder tumors.膀胱肿瘤患者尿液中脱落细胞的短期培养。

Urol Res. 1993 Jan;21(1):23-6. doi: 10.1007/BF00295187.

Prognostic factors in superficial bladder cancer.浅表性膀胱癌的预后因素

World J Urol. 1993;11(3):148-52. doi: 10.1007/BF00211409.

The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.肿瘤扩散、分级及生长模式作为膀胱癌形态学预测参数的价值。对1987年TNM分类的批判性修订。

J Cancer Res Clin Oncol. 1993;119(10):578-93. doi: 10.1007/BF01372721.

Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer.表皮生长因子受体、T138和T43表达在膀胱癌中的预后价值

Br J Cancer. 1995 Jan;71(1):196-200. doi: 10.1038/bjc.1995.40.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验